Model-based computational precision medicine to develop combination therapies for autoimmune diseases

References

• Barturen G, Beretta L, Cervera R, et al., Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol. 2018;14(2): 75–93.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Tabernero J. A precision approach to tumour treatment. Nature. 2017;548(7665):40–41.
   PubMed Web of Science ®Google Scholar
• Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23(9):1028–1035.
   PubMed Web of Science ®Google Scholar
• Wermuth PJ, Piera-Velazquez S, Rosenbloom J, et al. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat Rev Rheumatol. 2018;14(7):421–432.
   PubMed Web of Science ®Google Scholar
• Barturen G, Babaei S, Català-Moll F, et al., Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(6): 1073–1085.
   PubMed Web of Science ®Google Scholar
• Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340–350.
   PubMed Web of Science ®Google Scholar
• Sanz I, Lund F. Complexity and heterogeneity - the defining features of autoimmune disease. Curr Opin Immunol. 2019;61:iii–vi.
   PubMed Web of Science ®Google Scholar
• Smilek DE, Ehlers MR, Nepom GT. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech. 2014;7(5):503–513.
   PubMed Web of Science ®Google Scholar
• Patil S, Gs V, Sarode GS, et al. Exploring the role of immunotherapeutic drugs in autoimmune diseases: a comprehensive review. J Oral Biol Craniofac Res. 2021;11(2):291–296.
   PubMedGoogle Scholar
• Slight-Webb S, Bourn RL, Holers VM, et al. Shared and unique immune alterations in pre-clinical autoimmunity. Curr Opin Immunol. 2019;61:60–68.
   PubMed Web of Science ®Google Scholar
• Burmester GR. Rheumatology 4.0: big data, wearables and diagnosis by computer. Ann Rheum Dis. 2018;77(7):963–965.
   PubMed Web of Science ®Google Scholar
• Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell. 2020;181(1):63–80.
   PubMed Web of Science ®Google Scholar
• Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32–52.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, et al. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med. 2016;3(1):e000157.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–338.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Weinblatt ME, Bathon J, et al. Unmet need in rheumatology: reports from the targeted therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88–93.
   PubMed Web of Science ®Google Scholar
• Tamirou F, Houssiau FA. Management of lupus nephritis. J Clin Med. 2021;10(4):670.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3–18.
   PubMed Web of Science ®Google Scholar
• Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149.
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111–128.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DMFM, St. Clair EW, et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22): 1594–1602.
   PubMed Web of Science ®Google Scholar
• Teng YKO, Bruce IN, Diamond B, et al., Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9(3): e025687.
   PubMed Web of Science ®Google Scholar
• Heijden E, Blokland S, Hillen M, et al. Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren’s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2020;2:e260–69.
   Google Scholar
• Van der Heijden EH, Hartgring SA, Kruize AA, et al. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren’s syndrome. Expert Rev Clin Immunol. 2019;15(7):801–808.
   PubMed Web of Science ®Google Scholar
• Banchereau R, Hong S, Cantarel B, et al., Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(3): 551–565.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.
   PubMed Web of Science ®Google Scholar
• Pitoiset F, Cassard L, El Soufi K, et al. Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytometry A. 2018;93(8):793–802.
   PubMedGoogle Scholar
• Fang H, De Wolf H, Knezevic B, et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat Genet. 2019;51(7):1082–1091.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Guerrini MM, Yamamoto K. Functional genomics of autoimmune diseases. Ann Rheum Dis. 2021;80(6):689–697. annrheumdis-2019-216794.
   Web of Science ®Google Scholar
• Ruiz-Cerdá ML, Irurzun-Arana I, González-Garcia I, et al. Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach. Eur J Pharm Sci. 2016;94:46–58.
   PubMed Web of Science ®Google Scholar
• Noaiseh G, Baer AN. Toward better outcomes in Sjögren’s syndrome: the promise of a stratified medicine approach. Best Pract Res Clin Rheumatol. 2020;34(1):101475.
   PubMed Web of Science ®Google Scholar
• James JA, Guthridge JM, Chen H, et al. Unique Sjögren’s syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020;59(4):860–868.
   PubMed Web of Science ®Google Scholar
• Banchereau R, Cepika A-M, Pascual V. systems approaches to human autoimmune diseases. Curr Opin Immunol. 2013;25(5):598–605.
   PubMed Web of Science ®Google Scholar
• Kveler K, Starosvetsky E, Ziv-Kenet A, et al. Immune-centric network of cytokines and cells in disease context identified by computational mining of PubMed. Nat Biotechnol. 2018;36(7):651–659.
   PubMed Web of Science ®Google Scholar
• Toro-Domínguez D, Carmona-Sáez P, Alarcón-Riquelme ME. Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome uncovered through gene expression meta-analysis. Arthritis Res Ther. 2014;16(6):489.
   PubMed Web of Science ®Google Scholar
• Martin-Gutierrez L, Peng J, Thompson NL, et al. Two shared immune cell signatures stratify patients with Sjögren’s syndrome and systemic lupus erythematosus with potential therapeutic implications. Arthritis Rheumatol. 2021;73(9):1626–1637.
   PubMed Web of Science ®Google Scholar
• Soret P, Le Dantec C, Desvaux E, et al., A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome. Nat Commun. 2021;12(1): 3523.
   PubMed Web of Science ®Google Scholar
• Chaussabel D, Quinn C, Shen J, et al., A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29(1): 150–164.
   PubMed Web of Science ®Google Scholar
• Altman MC, Rinchai D, Baldwin N, et al. A novel repertoire of blood transcriptome modules based on co-expression patterns across sixteen disease and physiological states. bioRxiv. 2019;525709.
   Google Scholar
• Haynes WA, Haddon DJ, Diep VK, et al. Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus. JCI Insight. 2020;5(4):122312.
   PubMed Web of Science ®Google Scholar
• Aterido A, Cañete JD, Tornero J, et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to Anti-TNF Therapy in Rheumatoid Arthritis. Front Immunol. [Internet]. 2019 [cited 2021 Jul 13];10. Available from]. https://www.frontiersin.org/articles/10.3389/fimmu.2019.01459/full
   PubMed Web of Science ®Google Scholar
• Zheng J-N, Li Y, Yan Y-M, et al. Identification and validation of key genes associated with systemic sclerosis-related pulmonary hypertension. Front Genet. 2020;11:816.
   PubMed Web of Science ®Google Scholar
• Moinzadeh P, Frommolt P, Franitza M, et al. Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsets. J Eur Acad Dermatol Venereol. 2020;34(5):e236–e238.
   PubMed Web of Science ®Google Scholar
• Beretta L, Barturen G, Vigone B, et al. Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients. Ann Rheum Dis. 2020;79(9):1218–1226.
   PubMed Web of Science ®Google Scholar
• Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory disease. BMJ. 2018;360:j5145.
   PubMedGoogle Scholar
• Chen RY, Mostafa I, Hibberd MC, et al. Melding microbiome and nutritional science with early child development. Nat Med. 2021;27(9):1503–1506.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nowak JA, Hamada T, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018;67(6):1168–1180.
   PubMed Web of Science ®Google Scholar
• Ogino S, Nowak JA, Hamada T, et al. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019;14(1):83–103.
   PubMed Web of Science ®Google Scholar
• Stafford IS, Kellermann M, Mossotto E, et al. A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. Npj Digit Med. 2020;3(1):1–11.
   PubMed Web of Science ®Google Scholar
• Acosta-Herrera M, Kerick M, González-Serna D, et al. Genome-wide meta-analysis reveals shared new lociin systemic seropositive rheumatic diseases. Ann Rheum Dis. 2019;78(3):311–319.
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043.
   PubMed Web of Science ®Google Scholar
• Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and Strategies. Immunity. 2018;48(3):417–433.
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156. Published 2021 Sep 27
   PubMed Web of Science ®Google Scholar
• Attarian S, Vallat J-M, Magy L, et al. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2014;9(1):199.
   PubMedGoogle Scholar
• Chumakov I, Nabirotchkin S, Cholet N, et al. Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy. Sci Rep. 2015;5(1):7608.
   PubMedGoogle Scholar
• Hajj R, Milet A, Toulorge D, et al. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease. Sci Rep. 2015;5(1):16084.
   PubMedGoogle Scholar
• Bansal M, Yang J, Karan C, et al. A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol. 2014;32(12):1213–1222.
   PubMed Web of Science ®Google Scholar
• Zhao X-M, Iskar M, Zeller G, et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol. 2011;7(12):e1002323.
   PubMed Web of Science ®Google Scholar
• Celebi R, Movva R, Movva R, et al. In-silico prediction of synergistic anti-cancer drug combinations using multi-omics data. Sci Rep. 2019;9(1):8949.
   PubMedGoogle Scholar
• Huang L, Brunell D, Stephan C, et al. Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction. Bioinformatics. 2019;35(19):3709–3717.
   PubMed Web of Science ®Google Scholar
• Cheng F, Kovács IA, Barabási A-L. Network-based prediction of drug combinations. Nat Commun. 2019;10(1):1197.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang P, Qu XA, et al. Systematic prediction of drug combinations based on clinical side-effects. Sci Rep. 2014;4(1):7160.
   PubMedGoogle Scholar
• Zimmer A, Katzir I, Dekel E, et al. Prediction of multidimensional drug dose responses based on measurements of drug pairs. PNAS. 2016;113(37):10442–10447.
   PubMed Web of Science ®Google Scholar
• Ianevski A, Giri AK, Gautam P, et al. Prediction of drug combination effects with a minimal set of experiments. Nat Mach Intell. 2019;1(12):568–577.
   PubMedGoogle Scholar
• Steinman L, Merrill JT, McInnes IB, et al. Optimization of current and future therapy for autoimmune diseases. Nat Med. 2012;18(1):59–65.
   PubMed Web of Science ®Google Scholar
• Kurki P. Regulatory aspects of evaluating combination treatments in autoimmune diseases. Springer Semin Immunopathol. 2001;23(1–2):35–41.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmun Rev. 2019;18(1):93–106.
   PubMed Web of Science ®Google Scholar
• Mucke J, Sewerin P, Schneider M. Rheumatology in 2049: the age of all data. Ann Rheum Dis. 2021;80(7):825–827.
   PubMed Web of Science ®Google Scholar
• Moingeon P, Kuenemann M, Guedj M. Artificial intelligence enhanced drug design and development: towards a computational precision medicine. Drug Discov Today. 2021;20:S1359–6446.
   Google Scholar